[Lec] MU6: Opportunistic Mycoses Flashcards
Infections in patients with immune deficiencies who would otherwise not be infected
Opportunistic Mycoses
Infections seen in those people with impaired host defenses
Opportunistic Mycoses
Odd One Out:
Impaired Host Defenses
a. AIDS
b. Alteration of normal flora
c. Diabetes mellitus
d. Immunosuppressive therapy
e. Presence of indigenous microbiota
f. Malignancy
e. Presence of indigenous microbiota
(normal flora)
Type of Opportunistic Mycoses:
part of a normal human flora
Endogenous
Type of Opportunistic Mycoses:
fungus does not normally live in/on human body
Exogenous
Endogenous species
Candida albicans and other spp.
Pneumocystis jirovecii
Exogenous species
Cryptococcus neoformans
Aspergillus spp.
Zygomycetes
Candidiasis / Moniliasis:
causative agent
Candida albicans and other Candida spp.
What disease:
caused by Candida albicans and other Candida spp.
Candidiasis / Moniliasis
What species:
Oval, budding yeast that produces pseudohyphae
Candida albicans
What species:
causes the most frequent opportunistic fungal infections
Candida albicans
What species:
Harmless inhabitants of the skin and mucous membranes (RT, GIT, female genital tract)
Candida albicans
T/F:
Compromised immune system keeps Candida on body surfaces
F; normal immune system
Odd One Out:
Risk Factors for Candidiasis/Moniliasis
a. Neutropenia
b. Diabetes mellitus
c. AIDS
d. SCID
e. Antineoplastic therapy
e. Antineoplastic therapy;
RF for Pneumocystis
Odd One Out:
Risk Factors for Candidiasis/Moniliasis
a. Myeloperoxidase defects
b. Broad-spectrum antibiotics
c. Corticosteroid therapy
d. Indwelling catheters
e. Major surgery
c. Corticosteroid therapy
RF for Pneumocystis, Cryptococcosis/Torulosis, & Aspergillosis
Odd One Out:
Risk Factors for Candidiasis/Moniliasis
a. Organ transplantation
b. Hematological malignancy
c. Neonates
d. Severity of any illness
e. Intravenous drug addicts
b. Hematological malignancy;
RF for Cryptococcosis/Torulosis & Aspergillosis
What disease:
Although it is endogenous in most cases, cross infections are described, especially in intensive care unit patients
Candidiasis/Moniliasis
What disease:
Oral thrush, Oezophagitis, Vulvovaginal infection, Onychomycosis
Candidiasis/Moniliasis
(Cutaneous and Mucosal Candidiasis)
Cutaneous candidiasis:
seen in what types of patients?
skin trauma, burn patients
Mucocutaneous candidiasis
seen in what types of patients?
SCID patients
Choose 3: Invasive Candidiasis
a. Systemic
b. Disseminated
c. Cutaneous
d. Hematogenous
a. Systemic
b. Disseminated
d. Hematogenous
Invasive Candidiasis:
Usually begins with __________
candidemia
Candidemia:
* Only about ____% of cases can be proven
* Mortality is ____%
50% proven
30-40% mortality
T/F:
In invasive candidiasis, invasive infection stops in compromised phagocytic system.
F;
normal phagocytic system
T/F:
In normal phagocytic system of invasive candidiasis, infection spreads to many organs and causes focal infection in these organs.
F;
In compromised phagocytic system
Choose 4:
Defense mechanism against Candidiasis/Moniliasis
a. Skin and mucous membranes integrity
b. Presence of normal bacterial flora
c. Phagocytosis
d. Immune suppression
e. T-cells (CD4)
a. Skin and mucous membranes integrity
b. Presence of normal bacterial flora
c. Phagocytosis
e. T-cells (CD4)
T/F:
Defense mechanisms against Candidiasis/Moniliasis include killing, mostly in macrophagses, less in polymorphonuclear cells.
F;
killing mostly in polymorphonuclear cells, less in macrophages
Candidiasis/Moniliasis:
Specimen for lab diagnosis
CESS:
CSF
Exudates
Sputum
Swabs or Scrappings from lesions
What species:
Microscopic morphology: Gram (+) oval, budding yeast/ elongated budding cells in chain (pseudohyphae)
Candida spp
Candida spp:
appearance in SDA
soft, cream-colored colonies with a yeasty odor, surface growth consists of oval budding cells
Candidiasis/Moniliasis:
Ferments _______ and _______ producing acid and gas for lab diagnosis
glucose
maltose
Candidiasis/Moniliasis:
Serological test
Precipitation tests
Candidiasis/Moniliasis:
Treatment
FANC:
Fluconazole
Amphotericin B
Nystatin
Caspofungin
Candidiasis/Moniliasis:
Treatment for neutropenic patients
Amphotericin B
Candidiasis/Moniliasis:
Treatment for nonneutropenic patients
Fluconazole
Candidiasis/Moniliasis:
Treatment that suppresses intestinal and vaginal candidiasis
Nystatin
Pneumocystis Pneumonia:
causative agent
Pneumocystis jirovecii
What disease:
caused by Pneumocystis jirovecii
Pneumocystis Pneumonia
What species:
was formerly carinii and was previously classified as a protozoa but now considered a fungus based on nucleic acid and biochemical analysis
Pneumocystis jirovecii
What species:
Present in lungs of many mammals, including humans in persistent but harmless infection
Pneumocystis jirovecii
Odd One Out:
Risk Factors for Pneumocystis Pneumonia
a. Myeloperoxidase defects
b. AIDS
c. Transplantation
d. Corticosteroid
e. Antineoplastic therapy
a. Myeloperoxidase defects
RF for Candidiasis/Moniliasis
Pneumocystis:
Clinical manifestation
Interstitial pneumonitis (in compromised patients)
Pneumocystis:
Defense Mechanism
T-cell mediated
Pneumocystis Pneumonia:
Treatment
Co-trimoxazole
Pentamidine
Cryptococcosis/Torulosis:
causative agent
Cryptococcus neoformans
What disease:
caused by Cryptococcus neoformans
Cryptococcosis/Torulosis
What species:
Causes an acute or chronic infection that involves the brain
Cryptococcus neoformans
What species:
Occurs worldwide in soil and in bird droppings
Cryptococcus neoformans
What species:
Prominent feature is thick polysaccharide capsule, which causes evasion from phagocytosis
Cryptococcus neoformans
Odd One Out:
Risk Factors for Cryptococcosis/Torulosis
a. T-cell deficiency (AIDS patients)
b. Bone marrow transplantation
c. Corticosteroid therapy
d. Organ transplantation
e. Hematological malignancy
b. Bone marrow transplantation
RF for Aspergillosis
T/F:
Cryptococcosis/Torulosis is transmitted from human to human.
F
What disease:
A slowly developing chronic meningitis that resembles a brain tumor
Cryptococcosis/Torulosis